Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

338 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL: does estimated glomerular filtration rate matter?
Vergori A, Gagliardini R, Gianotti N, Gori A, Lichtner M, Saracino A, De Vito A, Cascio A, Di Biagio A, Monforte AD, Antinori A, Cozzi-Lepri A; ICONA Foundation Study Network. Vergori A, et al. Among authors: de vito a. Int J Antimicrob Agents. 2020 Dec;56(6):106154. doi: 10.1016/j.ijantimicag.2020.106154. Epub 2020 Sep 10. Int J Antimicrob Agents. 2020. PMID: 32919008
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study.
Rossetti B, Baldin G, Sterrantino G, Rusconi S, De Vito A, Giacometti A, Gagliardini R, Colafigli M, Capetti A, d'Ettorre G, Celani L, Lagi F, Ciccullo A, De Luca A, Di Giambenedetto S, Madeddu G. Rossetti B, et al. Among authors: de luca a, de vito a. Antiviral Res. 2019 Sep;169:104552. doi: 10.1016/j.antiviral.2019.104552. Epub 2019 Jul 5. Antiviral Res. 2019. PMID: 31283942 Free article.
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort.
d'Arminio Monforte A, Tavelli A, Cozzi-Lepri A, Castagna A, Passerini S, Francisci D, Saracino A, Maggiolo F, Lapadula G, Girardi E, Perno CF, Antinori A; Icona Foundation Study Group. d'Arminio Monforte A, et al. J Antimicrob Chemother. 2020 Mar 1;75(3):681-689. doi: 10.1093/jac/dkz512. J Antimicrob Chemother. 2020. PMID: 31865395
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marrocco-Trischitta MM, Ripamonti D, Binda F, Bonfanti P, Squillace N, Castelli F, Muiesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolongo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gargiulo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, Italy. Perrone F, et al. J Transl Med. 2020 Oct 21;18(1):405. doi: 10.1186/s12967-020-02573-9. J Transl Med. 2020. PMID: 33087150 Free PMC article. Clinical Trial.
HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients.
Malagnino V, Cerva C, Cingolani A, Ceccherini-Silberstein F, Vergori A, Cuomo G, Perno CF, Puoti M, d'Arminio Monforte A, Cozzi-Lepri A, Andreoni M, Sarmati L; ICONA Foundation Study Group. Malagnino V, et al. Open Forum Infect Dis. 2020 Nov 18;8(1):ofaa566. doi: 10.1093/ofid/ofaa566. eCollection 2021 Jan. Open Forum Infect Dis. 2020. PMID: 33447635 Free PMC article.
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort.
Bandera A, Lorenzini P, Taramasso L, Cozzi-Lepri A, Lapadula G, Mussini C, Saracino A, Ceccherini-Silberstein F, Puoti M, Quiros-Roldan E, Montagnani F, Antinori A, d'Arminio Monforte A, Gori A; Icona Foundation Cohort. Bandera A, et al. J Viral Hepat. 2021 May;28(5):779-786. doi: 10.1111/jvh.13488. Epub 2021 Mar 11. J Viral Hepat. 2021. PMID: 33600068
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study.
Taramasso L, De Vito A, Ricci ED, Orofino G, Squillace N, Menzaghi B, Molteni C, Gulminetti R, De Socio GV, Pellicanò GF, Sarchi E, Celesia BM, Calza L, Rusconi S, Valsecchi L, Martinelli CV, Cascio A, Maggi P, Vichi F, Angioni G, Guadagnino G, Cenderello G, Dentone C, Bandera A, Falasca K, Bonfanti P, Di Biagio A, Madeddu G; Behalf of the CISAI Study Group. Taramasso L, et al. Among authors: de socio gv, de vito a. AIDS Patient Care STDS. 2021 Sep;35(9):342-353. doi: 10.1089/apc.2021.0089. AIDS Patient Care STDS. 2021. PMID: 34524918
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marrocco-Trischitta MM, Ripamonti D, Binda F, Bonfanti P, Squillace N, Castelli F, Muiesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolongo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gargiulo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, Italy. Perrone F, et al. J Transl Med. 2021 Oct 21;19(1):442. doi: 10.1186/s12967-021-03094-9. J Transl Med. 2021. PMID: 34674735 Free PMC article. No abstract available.
338 results